BRONCHIECTASIS DRUGS MARKET ANALYSIS

Market Challenges And Opportunities

Bronchiectasis Drugs Market Drivers:

• Increasing Prevalence of Bronchiectasis: The rising prevalence of bronchiectasis worldwide is a significant driver for the market. Factors such as aging populations, improved diagnostics, and increased awareness of the condition contribute to the growing number of diagnosed cases. As the patient population expands, there is a higher demand for effective drugs to manage bronchiectasis symptoms and improve patients' quality of life. For instance, according to the data published by the National Center for Biotechnology Information (NCBI) on July 1, 2022, the prevalence of bronchiectasis has been found to range from 67 to 566.1 per 100,000 inhabitants in Europe and North America.
• Increasing Awareness of the Disease: Increasing awareness of the disease globally will aid in market growth over the forecast period. For instance, according to the data published by the National Center for Biotechnology Information (NCBI) on July 1, 2022, global lung health organizations from the USA, Europe, Australia, and Asia joined together to declare July 1, 2022 as the first ‘World Bronchiectasis Day’ to raise awareness about bronchiectasis. The motive of the day is to emphasize the increased prevalence of bronchiectasis globally and to increase awareness and promote effective diagnosis and management of this rather neglected disease.

Bronchiectasis Drugs Market Opportunities:

• Unmet Medical Needs: Despite advancements in treatment options, there are still unmet medical needs in the bronchiectasis drugs market. Opportunities exist for the development of novel drugs that can address specific challenges in managing the condition, such as reducing exacerbations, improving lung function, and enhancing quality of life for patients. Targeting these unmet needs can lead to the introduction of innovative therapies and drive market growth.
• Emerging Markets: There are growing opportunities in emerging markets, particularly in regions such as Asia Pacific, Latin America, and the Middle East. These markets have a rising prevalence of bronchiectasis and an increasing demand for effective treatment options. Expanding market reach to these emerging markets, adapting to local healthcare systems, and addressing specific regional needs can lead to significant market growth opportunities. For instance, according to the data published by the Korean Journal of Internal Medicine on June 16, 2021, the prevalence of idiopathic bronchiectasis was higher in Asia (59.2%) than in Europe (41.1%).

Bronchiectasis Drugs Market Restraints:

• Limited Awareness and Underdiagnosis: Bronchiectasis is often underdiagnosed or misdiagnosed, leading to delayed or inadequate treatment. Limited awareness among healthcare professionals and the general population about the condition can hinder early detection and appropriate management. The lack of recognition and understanding of bronchiectasis may result in a smaller market size than the actual patient population, impacting overall market growth. For instance, according to the data published by Springer Nature in 2021, underdiagnosis of obstructive lung disease (OLD) such as bronchiectasis is very common among French adults, even in patients with respiratory symptoms.
• Increasing awareness and increasing diagnosis of bronchiectasis will aid in the market growth over the forecast period.

• High Development Costs and Regulatory Hurdles: Developing and bringing new bronchiectasis drugs to market can be costly and time-consuming. The rigorous clinical trial process, regulatory requirements, and market access challenges can create barriers for pharmaceutical companies. The high development costs associated with conducting clinical trials and obtaining regulatory approvals can deter investment in research and development, limiting the availability of innovative therapies.

Recent Developments

Key Developments

• On July 18, 2023, Zambon, a multinational pharmaceutical company, announced the final results from the Phase 3 PROMIS-I and PROMIS-II studies, which were presented today at the 2023 6th World Bronchiectasis Conference in New York, NY.
• On November 23, 2020, RedHill Biopharma, a pharmaceutical company, launched a Phase 3 clinical trial to evaluate the safety and effectiveness of its investigational oral therapy, RHB-204, in adults with bronchiectasis.